Scroll's mainnet TVL drops to $863 million

Chicago wheat futures fell about 2.6%, soybean meal dropped 2.5%, and soybean oil rose over 1.3%.

Eli Lilly's Chief Financial Officer recently stated that its oral GLP-1 receptor agonist Orforglipron could enter the US market as early as the second quarter of this year, following expected regulatory approval in April.

Elliott Investment Management pointed out that Norwegian Cruise Line (NCLH) released a disappointing financial outlook for 2026, which shows a significant gap with the company's actual development potential.

Eli Lilly's Chief Financial Officer stated that once Orforglipron receives approval from the U.S. Food and Drug Administration (FDA), it is expected to take only about a week to complete the shipment of the drug to customers and patients.